Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004038 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00004038: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004038 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004038, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Combining chemotherapy with gene therapy may kill more tumor cells.
Interventions
- DRUG chemotherapy
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1999-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004038
The ClinicalTrials.gov registry entry for NCT00004038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00004038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004038 about?
NCT00004038 is a clinical study titled "Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer". Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Combining chemotherapy with ge...
What is the current status of trial NCT00004038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1999-01.
What interventions are being tested in trial NCT00004038?
The interventions under investigation include: chemotherapy (DRUG), Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004038?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.